Avenue therapeutics announces outcome of fda advisory committee meeting on iv tramadol

New york, feb. 15, 2022 (globe newswire) -- avenue therapeutics, inc. (nasdaq: atxi) (“avenue”), a company focused on the development of intravenous (“iv”) tramadol for the u.s. market, today announced the outcome of the u.s. food and drug administration (“fda”) joint meeting of the anesthetic and analgesic drug products advisory committee and the drug safety and risk management advisory committee on iv tramadol.
ATXI Ratings Summary
ATXI Quant Ranking